EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 91 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,... May 19, 2021 FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy March 16, 2023 Young Mom Gives Birth To Healthy Baby Boy In The Midst... June 26, 2020 Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma May 23, 2023 Load more HOT NEWS Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments Keeping progress in oncology on the agenda: ESMO honours recipients of... Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning
